Pediatrics Resident, PGY-3 Oklahoma Childrens Hospital at OU Health Bethany, Oklahoma, United States
Background: Bronchiolitis is a common viral respiratory illness in infants 0-2 years old and accounts for 18% of all hospitalizations in this age group. Treatment consists of supportive care. The American Academy of Pediatrics (AAP) bronchiolitis guidelines recommend against use of albuterol in patients with bronchiolitis. In practice, many pediatricians trial albuterol, and for some patients there is notable improvement in symptoms. Objective: To investigate if patient-specific characteristics are associated with improvement after albuterol in some patients hospitalized with bronchiolitis. Design/Methods: Our project has been approved by our hospital IRB. We are evaluating patients 0-24 months of age admitted to our children's hospital between January 2019 and December 2022 with a diagnosis of bronchiolitis. To date, we have analyzed data from 600 charts, dated June to December 2022. We are collecting data from electronic medical records, including patients’ ages and demographics, medical and family histories, viral testing, and if they had documented clinical and/or vital sign improvement after a trial of albuterol. Patients with congenital heart disease, trisomy 21, cystic fibrosis, or baseline oxygen requirement were excluded. Chi-squared tests are being used to compare the groups. We also plan to complete some multi-variable modeling to investigate further correlations.
